Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment
AC Garrido-Castro, NU Lin, K Polyak - Cancer discovery, 2019 - AACR
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …
to treat. To date, therapies directed to specific molecular targets have rarely achieved …
[HTML][HTML] Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Background The pivotal phase III ASCENT trial demonstrated improved survival outcomes
associated with sacituzumab govitecan (SG), an anti-trophoblast cell-surface antigen 2 (anti …
associated with sacituzumab govitecan (SG), an anti-trophoblast cell-surface antigen 2 (anti …
The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication
M Tarsounas, P Sung - Nature Reviews Molecular Cell Biology, 2020 - nature.com
The tumour suppressor breast cancer type 1 susceptibility protein (BRCA1) promotes DNA
double-strand break (DSB) repair by homologous recombination and protects DNA …
double-strand break (DSB) repair by homologous recombination and protects DNA …
[HTML][HTML] RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez… - Annals of …, 2018 - Elsevier
ABSTRACT Background BRCA1 and BRCA2 (BRCA1/2)-deficient tumors display impaired
homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents …
homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents …
Advances in the systemic treatment of triple-negative breast cancer
JM Lebert, R Lester, E Powell, M Seal, J McCarthy - Current oncology, 2018 - mdpi.com
Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are
often aggressive and associated with a poor prognosis. Molecular characterization, while …
often aggressive and associated with a poor prognosis. Molecular characterization, while …
[HTML][HTML] Current approaches in treatment of triple-negative breast cancer
HA Wahba, HA El-Hadaad - Cancer biology & medicine, 2015 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is diagnosed more frequently in younger and
premenopausal women and is highly prevalent in African American women. TNBC is a term …
premenopausal women and is highly prevalent in African American women. TNBC is a term …
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
L Perkhofer, J Gout, E Roger, FK de Almeida… - Gut, 2021 - gut.bmj.com
Complex rearrangement patterns and mitotic errors are hallmarks of most pancreatic ductal
adenocarcinomas (PDAC), a disease with dismal prognosis despite some therapeutic …
adenocarcinomas (PDAC), a disease with dismal prognosis despite some therapeutic …
A mechanism for the suppression of homologous recombination in G1 cells
A Orthwein, SM Noordermeer, MD Wilson, S Landry… - Nature, 2015 - nature.com
DNA repair by homologous recombination is highly suppressed in G1 cells, to ensure that
mitotic recombination occurs solely between sister chromatids. Although many homologous …
mitotic recombination occurs solely between sister chromatids. Although many homologous …
[HTML][HTML] Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display
variable sensitivity to therapeutics and may play different roles in progression. We previously …
variable sensitivity to therapeutics and may play different roles in progression. We previously …